(Q42448698)

31 October 2017

title

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients (English)

1 reference

31 October 2017

M Muratori

1

1 reference

31 October 2017

M Arosio

2

1 reference

31 October 2017

G Gambino

3

1 reference

31 October 2017

C Romano

4

1 reference

31 October 2017

O Biella

5

1 reference

31 October 2017

G Faglia

6

1 reference

31 October 2017

publication date

1 October 1997

1 reference

Journal of Endocrinological Investigation

31 October 2017

published in

1 reference

31 October 2017

volume

20

1 reference

31 October 2017

issue

9

1 reference

31 October 2017

page(s)

537-546

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03348016

31 October 2017

exact match

0 references

cites work

Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Resistance to bromocriptine in prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Should dopamine agonist treatment for prolactinomas be life-long?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

The 7315a Pituitary Tumor Is Refractory to Dopaminergic Inhibition of Prolactin Release But Contains Dopamine Receptors*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Selective deficiency of guanine nucleotide-binding protein Go in two dopamine-resistant pituitary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: in vitro ultrastructural, morphometric, and immunoelectron microscopic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348016

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

21 January 2018

1 reference

12 December 2020

Drug therapy: Bromocriptine

1 reference

12 December 2020

Bromocriptine treatment of acromegaly

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

Effect of different dopaminergic agents in the treatment of acromegaly

1 reference

12 December 2020

Enlargement of a prolactin-secreting pituitary microadenoma during bromocriptine treatment. Case report

1 reference

12 December 2020

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine

1 reference

12 December 2020

Differential transduction of dopamine signal in different subtypes of human growth hormone-secreting adenomas

1 reference

12 December 2020

Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study

1 reference

12 December 2020

The neuroendocrine control of the menstrual cycle.

1 reference

12 December 2020

Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography

1 reference

12 December 2020

Cabergoline treatment of acromegaly: a preliminary dose finding study

1 reference

12 December 2020

Growth hormone and prolactin secretion in acromegaly: correlations between hormonal dynamics and immunocytochemical findings

1 reference

12 December 2020

Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride

1 reference

12 December 2020

Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases

1 reference

12 December 2020

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

12 December 2020

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration

1 reference

12 December 2020

Necrotic changes in prolactinomas after long term administration of bromocriptine

1 reference

12 December 2020

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

12 December 2020

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

12 December 2020

A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03348016

1 reference

Dimensions Publication ID

31 October 2017

1025303098

0 references

1 reference